The global Wilson disease drugs market is expected to grow at a CAGR of 4.5% during the forecast period (2022-2028). Various strategies adopted by the key players and FDA-approved drugs for the treatment of Wilson’s disease are supporting the growth of the global Wilson disease drugs market. For instance, in May 2022, the US FDA approved Cuvrior for the treatment of stable Wilson diseases in adults, who are decoppered and tolerant to penicillamine. The Cuvrior contains trientine, a copper chelator that eliminates absorbed copper from the human body by forming a stable complex, which is eliminated from urine excretion. Cuvrior is supplied as a functionally scored tablet containing 300mg of trientine tetrahydrochloride. The product is expected to be available in early 2023.
Get Free Sample link @ https://www.omrglobal.com/request-sample/wilson-disease-drugs-market
Vivet Therapeutics and Pfizer announced the US FDA has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson’s disease in august 2021. VTX-801 is a novel investigational gene therapy, which is evaluated in a phase ½ clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion. Pfizer is collaborating with Vivet on the clinical supply of VTX-801 for the phase ½ clinical trial.
A full report of Global Wilson Disease Drugs Market available @ https://www.omrglobal.com/industry-reports/wilson-disease-drugs-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Global Wilson Disease Drugs Market Report by Segment
By Drug Type
- Chelating Agents
- Zinc
- Tetrathiomolybdate
By Route of Administration
- Oral
- Parenteral
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Global Wilson Disease Drugs Market by Region
North America
- US
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Wilson disease drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/wilson-disease-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
